Abstract: It is provided a composition comprising a hyperbranched polyester polyol derivative and a small molecule comprising at least one cyclic amine. The hyperbranched polyester polyol derivative is obtainable by a method comprising the following steps: a) reacting only glycidol and ?-caprolactone at a temperature lying in a range of between 40° C. and 140° C. to obtain a hyperbranched polyester polyol derivative in which caprolactone residues and glycerol residues are randomly arranged; b) reacting the hyperbranched polyester polyol derivative of step a) with a sulfation reagent to obtain a sulfated hyperbranched polyester polyol as hyperbranched polyester polyol derivative.

Abstract: An amphiphilic copolymer includes a first block, a second block and a linker covalently linking the first block with the second block, wherein the first block is a hydrophilic dendritic polyglycerol derivative having a polyglycerol backbone and carrying a plurality of sulfate or sulfonate residues substituting hydroxyl groups of the polyglycerol backbone, wherein the second block is a hydrophobic block comprising a polymer chosen from the group consisting of polycaprolactone, a polylactic acid polymer, and a copolymer of lactic acid and glycolic acid. The linker comprises a hydrocarbon having at least six consecutive methylene residues and a cleavable entity. The linker is devoid of a triazole-containing residue resulting from a reaction between an alkyne and an azide.

Abstract: The present invention relates to novel dendrimer conjugates, methods for their preparation and their use for treatment of diseases. The invention discloses a new method for the delivery of dendrimer conjugates with therapeutically active molecules into the cell by utilizing transmembrane solute carrier proteins enabling uptake of the inventive dendrimer conjugates. Particular subject-matter of the present invention is a conjugate of the formula E-[G-L-D(OSO3?M+)n]m, wherein E is a therapeutic or diagnostic effector molecule, wherein D(OSO3?M+)n is a dendrimer D carrying a number n of sulfate groups OSO3?M+, wherein the number n of sulfate groups is selected from 6 to 96, wherein M is a cationic inorganic or organic counter ion to the anionic sulfate group, wherein L is a linker or spacer between D and E, wherein G is a connecting functional group forming the attachment between L and E, and wherein m is an integer from 1 to 20.

Abstract: The present invention relates to novel dendrimer conjugates, methods for their preparation and their use for treatment of diseases. The invention discloses a new method for the delivery of dendrimer conjugates with therapeutically active molecules into the cell by utilizing transmembrane solute carrier proteins enabling uptake of the inventive dendrimer conjugates. Particular subject-matter of the present invention is a conjugate of the formula E-?G-L-D(OSO3?M+)n?m, wherein E is a therapeutic or diagnostic effector molecule, wherein D(OSO3?M+)n is a dendrimer D carrying a number n of sulfate groups OSO3?M+, wherein the number n of sulfate groups is selected from 6 to 96, wherein M is a cationic inorganic or organic counter ion to the anionic sulfate group, wherein L is a linker or spacer between D and E, wherein G is a connecting functional group forming the attachment between L and E, and wherein m is an integer from 1 to 20.

Abstract: The present invention relates generally to methods and compositions for targeting of intracellular molecules involved in proliferation and protein synthesis of activated cells using polyanionic multivalent macromolecules. In particular aspect, multiple sulfate groups linked to polyol are specifically targeted to the cytoplasm and nucleus of proliferating and activated cells. The invention further comprises novel polyanionic macromolecular compounds and formulations.

Abstract: The present invention relates generally to methods and compositions for targeting of intracellular molecules involved in proliferation and protein synthesis of activated cells using polyanionic multivalent macromolecules. In particular aspect, multiple sulfate groups linked to polyol are specifically targeted to the cytoplasm and nucleus of proliferating and activated cells. The invention further comprises novel polyanionic macromolecular compounds and formulations.

Abstract: The present invention concerns the use of indocarbocyanine dyes, in particular indotricarbocyanine dyes for the diagnosis of inflammatory diseases, in particular rheumatoid arthritis, methods of diagnosing inflammatory diseases and an apparatus useful to carry out the method of diagnosing.

Abstract: Subject of the present invention are polyether polyol dendron conjugates comprising a specific polyether polyol dendron moiety, at least one certain fluorescent effector molecule (E). Such polyether polyol dendron conjugates may be used for diagnostic and therapeutic purposes, whereby the optical properties of the at least one certain fluorescent effector molecule are enhanced due to the attachment to the polyether polyol dendron conjugate.

Abstract: The present invention concerns the use of indocarbocyanine dyes, in particular indotricarbocyanine dyes for the diagnosis of inflammatory diseases, in particular rheumatoid arthritis, methods of diagnosing inflammatory diseases and an apparatus useful to carry out the method of diagnosing.

Abstract: The present invention concerns the use of the cyanine dye SF64 for the diagnosis of proliferative diseases upon administration of less than 5 mg/kg body weight.

Abstract: The present invention concerns the use of indocarbocyanine dyes, in particular indotricarbocyanine dyes for the diagnosis of inflammatory diseases, in particular rheumatoid arthritis, methods of diagnosing inflammatory diseases and an apparatus useful to carry out the method of diagnosing.

Abstract: The present invention concerns the use of the cyanine dye SF64 for the diagnosis of proliferative diseases upon administration of less than 5 mg/kg body weight.

Abstract: The invention relates to anthranilic acid amides and the use thereof as medicaments for the treatment of diseases that are triggered by persistent angiogenesis, in addition to intermediate products in the production of anthranilic acid amides.

Abstract: This invention relates to the use of conjugates of cyanine dyes with an angiogenesis specific binding component preferably with an EB-D fibronectin specific binding component for the diagnosis of micrometastasis and small proliferative lesions, in particular primary tumors, precancerosis, dysplasia, metaplasia, inflammatory lesions, e.g. psoriasis, psoriatic arthritis and/or rheumatoid arthritis, endometriotic lesions, and ocular diseases associated with angiogenesis.

Abstract: Disclosed are epothilone compounds of formula I, which are useful as pharmaceutical compounds for treating, for example, malignant tumors and chronic inflammatory diseases and are useful in anti-angiogenesis therapy.

Abstract: Disclosed are epothilone compounds of formula I, which are useful as pharmaceutical compounds for treating, for example, malignant tumors and chronic inflammatory diseases and are useful in anti-angiogenesis therapy.

Abstract: A compound of formula C, BC and ABC.

Abstract: A compund of formula I, an epothilone derivative, its method of preparation, and use as a pharmaceutical agent in treating malignant tumors

Abstract: This invention relates to emitter-binding peptides that produce a change in the spectral emission properties of the emitter in the case of an interaction of its antigen-binding pocket with the emitter. The emitter-binding peptides of the invention are in particular components of antibodies and antibody fragments.

Abstract: This invention relates to a device and a process for direct quantitative in vitro determination of a substance that is contained in a sample. The device according to the invention comprises agents, immobilized on a surface, for detecting substances, a free substance-emitter conjugate, and agents, immobilized on a surface, for detecting the emitter. The emitter of the device that is used comprises a portion that reacts with a change in the emission properties in an interaction with the agent for detecting the emitter. By means of the device according to the invention, substances that are selected from antigens, such as proteins, peptides, nucleic acids, oligonucleotides, blood components, serum components, lipids, pharmaceutical agents and compounds of low molecular weight or, in another design, substance-detecting agents, such as, for example, antibodies or fragments thereof, can be determined directly quantitatively, in, e.g., whole-blood samples.